Anti-IL-5 [SB-240563 (Mepolizumab)]

Absolute Antibody

Anti-IL-5 [SB-240563 (Mepolizumab)]

9

This antibody recognizes and binds human interleukin-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. This antibody does not cross react with mouse IL-5.

The pharmacokinetics of this antibody was investigated after intravenous and subcutaneous administration to cynomolgus monkeys. Suppression of eosinophil count was observed after multiple monthly administrations of this antibody to monkeys (PMID: 10565825). Pre-clinical efficacy and safety studies in cynomolgus monkeys demonstrated that chronic antagonism of IL-5 by mepolizumab is safe and has the potential to be beneficial therapy for chronic inflammatory respiratory diseases (PMID: 11496242). In a double-blind randomized placebo-controlled trial, the effects of treatment on responses to inhaled allergen challenge, sputum eosinophils, and airway hyper-responsiveness to histamine were measured at weeks 1 and 4 after a single intravenous infusion of this antibody. This antibody lowered the mean blood eosinophil count in placebo group and prevented the blood eosinophilia that follows allergen challenge. It also significantly reduced sputum eosinophilia seen after inhaled allergen challenge. It was further reported that this antibody had no significant effect to IL-5 on the late asthmatic response or on airway hyperresponsiveness to histamine (PMID: 11191542). In a double blind placebo-controlled study in asthmatic patients this antibody markedly reduced peripheral blood eosinophils without altering the distribution and activation status of lymphocytes (PMID: 12765424).

Research Use Only

Monoclonal

SB-240563 (Mepolizumab)

IL5

interleukin 5

B-cell differentiation factor I; colony-stimulating factor, eosinophil; EDF; eosinophil differentiation factor; IL-5; interleukin-5; T-cell replacing factor; TRF

Rabbit

IgG

Interleukin-5

Human

-20°C,2°C to 8°C

12352203